- In September 25, 2023, NervGen Pharma Corporation, a clinical-stage biotech company focused on treatments for nervous system damage, announced that the first participant had been dosed in their landmark Phase 1b/2a placebo-controlled clinical trial for NVG-291, their lead compound for spinal cord injury (SCI)
- In August 2023, Kaneka Corporation, an international chemical manufacturer based in Japan, initiated a Phase I/II clinical trial for KA-301, a treatment for acute spinal cord injury derived from human amnion-based mesenchymal stem cells. The cell preparations for this trial were developed through technology supported by Japan’s Science and Technology Agency (JST) under the NexTEP program
- In July 2023, NeuroSolv Therapeutics, based in Belfast, Northern Ireland, and Baltimore, U.S., partnered with AscellaHealth LLC, a global healthcare and specialty pharmacy solutions company. The collaboration aims to expand NeuroSolv’s clinical trial development program and expedite regulatory approval processes, with the goal of accelerating the market launch of their product, Perineline
- In June 2022, Amneal Pharmaceuticals, Inc. announced the commercial launch of LYVISPAH, an FDA-approved baclofen oral granules product (available in 5, 10, and 20 mg doses) designed to treat spasticity associated with multiple sclerosis and other spinal cord disorders
- In August 2021, Novartis AG announced that the FDA had lifted the partial clinical trial hold, originally imposed in October 2019, allowing the OAV-101 intrathecal (IT) clinical trials for spinal muscular atrophy (SMA) patients to resume
- In July 2021, Mitsubishi Tanabe Pharma Corporation, a global pharmaceutical company, received fast track designation from the U.S. FDA for MT-3921, a treatment under development for spinal cord injury
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Complete Spinal Cord Injury and Incomplete Spinal Cord Injury), Treatment Type (Corticosteroid, Surgery, and Spinal Traction), End User (Hospitals and Trauma Centers) – Industry Trends and Forecast to 2031
.
The Global Acute Spinal Cord Injury Market size was valued at USD 7.58 USD Billion in 2023.
The Global Acute Spinal Cord Injury Market is projected to grow at a CAGR of 5.4% during the forecast period of 2024 to 2031.
The major players operating in the market include Novartis AG, Tenax Therapeutics, Accure Pharma, Acorda Therapeutics , Asterias Biotherapeutics, ReNetX Bio, BioArctic AB, BioTime , InVivo Therapeutics, Kringle Pharma , BioAxone, AO Foundation, Pfizer , Pharmicell Co Ltd, Vertex Pharmaceuticals , Axoltis, KSTEMCELL Co Ltd, Wakayama Medical University.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
